Appendix (anatomy)

ENEL ANNOUNCES EARLY TENDER RESULTS OF ITS TENDER OFFER FOR U.S.$1,250,000,000 8.750% CAPITAL SECURITIES DUE 2073

Retrieved on: 
Tuesday, January 24, 2023
USD, Depository Trust Company, Global Securities Lending, Collection, Citibank, Receipt, Failure, Cession, ENEL, Security (finance), Cede and Company, Certification, VOI, Importance, Swanson v. Citibank N.A., Depository Trust & Clearing Corporation, Appendix (anatomy), Tender offer, DTC

The solicitation of offers to sell the Securities is only being made pursuant to the terms of the Offer to Purchase.

Key Points: 
  • The solicitation of offers to sell the Securities is only being made pursuant to the terms of the Offer to Purchase.
  • Holders of USD Securities should also be aware of the tax formalities below.
  • The USD Securities are evidenced by one or more global securities (the "Global Securities") registered in the name of Monte Titoli S.p.A. ("Monte Titoli"), as operator of the Italian central securities clearing system.
  • See "Important Information Regarding the Tender Offers" and "Certain Italian Tax Considerations" and "Appendix A" included in the Offer to Purchase.

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Retrieved on: 
Thursday, December 15, 2022
Biogen, Corporations Act 2001, Psychiatry, Social anxiety disorder, Employment, Michele Cavion, CNS, ASX, Extraordinary general meeting, School, Public sector, Faculty, EVP, Central nervous system disease, Central nervous system, Vigil, Doctor of Philosophy, Neurology, BNO, Pfizer, SVP, EGM, MD, Neurodegeneration, Corporation, BNC210, Non-executive director, Hotel des Indes (The Hague), Allergan, Appendix (anatomy), Post-traumatic stress disorder, Therapy, FOR, University, Development, Patient, Pharmaceutical industry, Security (finance), Bionomics, Appendix

as President and Chief Executive Officer (CEO), effective 5 January 2023.

Key Points: 
  • as President and Chief Executive Officer (CEO), effective 5 January 2023.
  • Spyros is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 25-year career focused on CNS disorders.
  • Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion.
  • The additional options are part of the compensation of Dr. De Souza for his period as Executive Chair of Bionomics.

Clover Health Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Review, Chamath Palihapitiya, Forecasting, Star, Forward-looking statement, Method, Investment, Risk, U.S. Securities and Exchange Commission, HMO, Adoption, SG, Investor relations, MA, COVID-19, Securities Act of 1933, Decision-making, Mission statement, SEC, Annual report, MCR, NASDAQ, Securities & Exchange Commission of Pakistan, Securities Exchange Act of 1934, Time, Company, Adjustment, Appendix (anatomy), Health equity, GAAP, Physician, Patient, PPO, Employee Retirement Income Security Act of 1974, Security (finance), Industry, CMS, Life insurance, Pharmaceutical industry, Bank, Health insurance, Clover, Medicare, Appendix, Insurance

"Third quarter financial results were highlighted by strong Insurance MCR performance, outsized revenue growth, and continued moderation of Adjusted SG&A growth," said Clover Health CFO Scott Leffler.

Key Points: 
  • "Third quarter financial results were highlighted by strong Insurance MCR performance, outsized revenue growth, and continued moderation of Adjusted SG&A growth," said Clover Health CFO Scott Leffler.
  • Clover Health's management will host a conference call to discuss its financial results on Monday, November 7, at 5:00 PM Eastern Time.
  • These non-GAAP financial measures are provided to enhance the reader's understanding of Clover Health's past financial performance and our prospects for the future.
  • Clover Health's management team uses these non-GAAP financial measures in assessing Clover Health's performance, as well as in planning and forecasting future periods.

Clover Health Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
MCR, Securities & Exchange Commission of Pakistan, Employee Retirement Income Security Act of 1974, Risk, Investor relations, PPO, Industry, Decision-making, CEO, Forward-looking statement, Technology, Growth, Securities Exchange Act of 1934, SEC, Chamath Palihapitiya, Security (finance), Annual report, HMO, Method, General counsel, Patient, EBITDA, Review, COVID-19, Company, Mission statement, U.S. Securities and Exchange Commission, Appendix (anatomy), CMS, NASDAQ, Forecasting, GAAP, Securities Act of 1933, Physician, Clover, Time, Adoption, Health insurance, Bank, Medicare, Insurance, Appendix

FRANKLIN, Tenn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to improving health equity for seniors, today reported financial results for the second quarter of 2022. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.

Key Points: 
  • In addition to hiring a Chief Technology Officer, Conrad Wai, and a General Counsel, Joseph Martin, during the first quarter of the year, Clover Health announced the appointment of Aric Sharp (CEO of Value Based Care) and Scott Leffler (Chief Financial Officer) during the second quarter of 2022.
  • Clover Health's management will host a conference call to discuss its financial results on Monday, August 8, at 5:00 PM Eastern Time.
  • These non-GAAP financial measures are provided to enhance the reader's understanding of Clover Health's past financial performance and our prospects for the future.
  • Clover Health's management team uses these non-GAAP financial measures in assessing Clover Health's performance, as well as in planning and forecasting future periods.

PJSC RusHydro: Results of the Board of Directors Meeting on February 28, 2022

Retrieved on: 
Saturday, March 5, 2022
LSE, Concept, Financial Oversight and Management Board for Puerto Rico, Investment, Appendix, KPI-driven code analysis, Methodology, Risk, OTCQX, Minutes, Board of directors, MAR, Business plan, Board, Company, Public–Private Investment Program for Legacy Assets, Appendix (anatomy), PJSC, Master production schedule, Performance, Russian Venture Company, Program, Electricity, RusHydro, RES, Online gambling, Medical device, Renewable energy, Management, Airline, Risk management, EU

PJSC RusHydro: Results of the Board of Directors Meeting on February 28, 2022

Key Points: 
  • PJSC RusHydro: Results of the Board of Directors Meeting on February 28, 2022
    Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
  • Results of the Board of Directors Meeting on February 28, 2022
    PJSC RusHydro (ticker symbol: MOEX, LSE: HYDR; OTCQX: RSHYY) announces that the Company's Board of Directors held a meeting on February 28, 2022.
  • 1.3.The list of annual key performance indicators and indicators for depressing the RusHydro Management Board Members for 2022 shall be according to the Appendix No.
  • **Approved by resolution of the RusHydro Board of Directors on June 30, 2020 (Minutes from 01.10.2020 No.

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics

Retrieved on: 
Thursday, March 3, 2022
Sleep apnea, Private Securities Litigation Reform Act, IHL, Mental health, U.S. FDA, Rheumatoid arthritis, Research, Response, Virtual reality, Appendix (anatomy), Asthma, Safety, Inflammatory bowel disease, Brain, University, OSA, Monash University Faculty of Medicine, Nursing and Health Sciences, FDA, ASX, Exposure, Monash University, ERP, Patent, COPD, Bronchitis, Environment, Clinical trial, Anxiety, Genta (company), Partnership, GAD, TBI, Department, VR, Pharmaceutical industry, Medical imaging, Appendix

MELBOURNE, Australia, March 3, 2022 /PRNewswire/ --Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced it has executed a license agreement with Monash University ('Monash University' or 'Monash') to develop a novel treatment that combines Virtual Reality ('VR') and psychedelics.

Key Points: 
  • MELBOURNE, Australia, March 3, 2022 /PRNewswire/ --Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced it has executed a license agreement with Monash University ('Monash University' or 'Monash') to develop a novel treatment that combines Virtual Reality ('VR') and psychedelics.
  • The license allows Incannex to investigate the use of the VR therapy tool in combination with a psychedelic drug to develop a new treatment for severe forms of one or more anxiety disorders.
  • The established VR treatment uses an exposure-based approach, providing triggering stimuli in a graded and controlled manner (Exposure and Response Prevention or ERP).
  • Three license fees are outlined in the agreement and payable upon the decision by Incannex to proceed to subsequent phases of the research program.

Southwestern Energy Completes Acquisition of GEP Haynesville

Retrieved on: 
Friday, December 31, 2021
Oil, Gas, Energy, Safety, Industry, COVID-19, Appendix (anatomy), Legislation, Risk, Sumathi Best Television Current Reporting Award, LLC, Tax, Person, Health, Statistics, Company, Nature, Natural gas, Appendix, News, SEC, Climate, Annual report, Regulation, NYSE, Federal Lands Jobs and Energy Security Act, Securities Exchange Act of 1934, Acquisition, Mission statement, Judgement, EBITDA, London Interbank Bid Rate, Weather, Securities Act of 1933, Risk management, SWN

Southwestern Energy Company (NYSE: SWN) (the Company) today announced that it has closed the acquisition of GEP Haynesville, LLC (GEP).

Key Points: 
  • Southwestern Energy Company (NYSE: SWN) (the Company) today announced that it has closed the acquisition of GEP Haynesville, LLC (GEP).
  • The Company expects to issue 2022 guidance inclusive of the acquired properties in conjunction with its fourth quarter earnings release.
  • Southwestern Energy Company (NYSE: SWN) is a leading U.S. producer and marketer of natural gas and natural gas liquids focused on responsibly developing large-scale energy assets in the nations most prolific shale gas basins.
  • SWNs returns-driven strategy strives to create sustainable value for its stakeholders by leveraging its scale, financial strength and operational execution.

Southwestern Energy Announces Derivative Position Added to Support Acquisition Financing

Retrieved on: 
Monday, November 29, 2021
Oil, Gas, Energy, Haynesville, Judgement, News, Safety, Sumathi Best Television Current Reporting Award, Federal Lands Jobs and Energy Security Act, Industry, Annual report, Climate, Acquisition, EBITDA, NYSE, Securities Exchange Act of 1934, Health, Mission statement, Weather, SEC, Nature, COVID-19, Regulation, Legislation, Tax, Risk, London Interbank Bid Rate, LLC, LP, Person, Appendix, Failure, Securities Act of 1933, Loss, Statistics, Appendix (anatomy), Natural gas, Risk management, Southwestern Energy, GEP Haynesville, SOUTHWESTERN ENERGY, GEP HAYNESVILLE

Southwestern Energy Company (NYSE: SWN) is a leading U.S. producer of natural gas and natural gas liquids focused on responsibly developing large-scale energy assets in the nations most prolific shale gas basins.

Key Points: 
  • Southwestern Energy Company (NYSE: SWN) is a leading U.S. producer of natural gas and natural gas liquids focused on responsibly developing large-scale energy assets in the nations most prolific shale gas basins.
  • SWNs returns-driven strategy strives to create sustainable value for its stakeholders by leveraging its scale, financial strength and operational execution.
  • These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us.
  • These estimates and assumptions reflect our best judgment based on currently known market conditions, operating trends, and other factors.

Southwestern Energy Announces Agreement to Acquire GEP Haynesville

Retrieved on: 
Thursday, November 4, 2021
Oil, Gas, Energy, Slate, Safety, JPMorgan Chase, Failure, Appendix (anatomy), London Interbank Bid Rate, Weather, Sumathi Best Television Current Reporting Award, Credit Suisse, Central, Climate, Nature, Wells Fargo, Regulation, COVID-19, Multimedia, Program, Health, Energy Independence and Security Act of 2007, Acquisition, RBC, Tax, Kirkland & Ellis, Judgement, EBITDA, Loss, GEP, GAAP, Public expenditure, Skadden, Henry Hub, Income, Annual report, Company, Bank of America, Goldman Sachs, Statistics, Industry, Mission statement, NYSE, SEC, USA, Risk, LLC, WTI, Appendix, News, Sale, Legislation, Securities Exchange Act of 1934, Bank, Securities Act of 1933, Risk management, NYMEX, Person, Citigroup, Policy, LP, Depreciation, G&A, Natural gas, Financial services, Oil, Lithium, Online gambling, Southwestern Energy, GEP Haynesville, SOUTHWESTERN ENERGY, GEP HAYNESVILLE

Southwestern Energy Company (NYSE: SWN) (the Company or Southwestern) today announced that it has entered into a definitive agreement with the third largest private Haynesville producer GEP Haynesville, LLC (GEP) under which it will acquire GEP for approximately $1.85 billion.

Key Points: 
  • Southwestern Energy Company (NYSE: SWN) (the Company or Southwestern) today announced that it has entered into a definitive agreement with the third largest private Haynesville producer GEP Haynesville, LLC (GEP) under which it will acquire GEP for approximately $1.85 billion.
  • The stock consideration consists of approximately 99 million shares of Southwestern Energy common stock, calculated utilizing the 30-day volume-weighted average price of $5.285 as of November 2, 2021.
  • The transaction was unanimously approved by each of Southwestern Energys and GEP Haynesvilles boards of directors.
  • In 2022, Southwestern Energy expects to continue with maintenance capital investment, averaging approximately 4.7 Bcfe per day of production.

Clover Health Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 11, 2021
Expense, MCR, Salary, COVID, Derivative, CMS, Risk, General officer, Center, Depreciation, Star, Process, COVID-19, Utilization, MA, DCE, Medicaid, Contract, Company, Amortization, GAAP, EBITDA, Direct, Physician, Medicare, Maintenance, Reduction, Pro forma, Net, Centers for Medicare & Medicaid Services, Appendix (anatomy), Pharmaceutical industry, Risk management, Security (finance), Insurance, Health insurance, Life insurance

NASHVILLE, Tenn., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Clover Health (Nasdaq: CLOV) ("Clover" or the "Company"), a next-generation healthcare company focused on improving health outcomes for America's seniors, today reported financial results for the second quarter of 2021. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.

Key Points: 
  • Non-GAAP financial measures are supplemental to and should not be considered a substitute for financial information presented in accordance with GAAP.
  • (2) In second quarter 2021, the Company updated its calculation of Normalized MCR (Non-GAAP) to reflect an estimate of the COVID-19 pandemic's impact on the Company's premium revenue.
  • UM (Utilization Management) Process Changes This consists of our estimate of the impact of process deterioration in our utilization management program during the first and second quarter of 2021.
  • Revenue under Clover Assistant Management - Annualized revenues related to Medicare Advantage members and Original Medicare beneficiaries attributed to CA physicians or practices live on the Clover Assistant on or before June 30, 2021.